company background image
BELL

Belluscura AIM:BELL Stock Report

Last Price

UK£0.89

Market Cap

UK£107.3m

7D

6.0%

1Y

59.5%

Updated

25 Jun, 2022

Data

Company Financials +
BELL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

BELL Stock Overview

Belluscura plc develops and commercialize oxygen related medical device products.

Belluscura Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Belluscura
Historical stock prices
Current Share PriceUK£0.89
52 Week HighUK£1.52
52 Week LowUK£0.56
Beta0
1 Month Change0%
3 Month Change-11.50%
1 Year Change59.46%
3 Year Changen/a
5 Year Changen/a
Change since IPO66.98%

Recent News & Updates

Shareholder Returns

BELLGB Medical EquipmentGB Market
7D6.0%2.2%2.3%
1Y59.5%-23.0%-8.6%

Return vs Industry: BELL exceeded the UK Medical Equipment industry which returned -23% over the past year.

Return vs Market: BELL exceeded the UK Market which returned -8.6% over the past year.

Price Volatility

Is BELL's price volatile compared to industry and market?
BELL volatility
BELL Average Weekly Movement8.6%
Medical Equipment Industry Average Movement5.6%
Market Average Movement5.5%
10% most volatile stocks in GB Market10.8%
10% least volatile stocks in GB Market2.8%

Stable Share Price: BELL is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: BELL's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
20156Bob Raukerhttps://www.belluscura.com

Belluscura plc develops and commercialize oxygen related medical device products. The company offers X-PLO2R, a modular portable oxygen concentrator. Belluscura plc was incorporated in 2015 and is based in London, the United Kingdom.

Belluscura Fundamentals Summary

How do Belluscura's earnings and revenue compare to its market cap?
BELL fundamental statistics
Market CapUS$131.86m
Earnings (TTM)-US$5.21m
Revenue (TTM)US$420.32k

314.4x

P/S Ratio

-25.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BELL income statement (TTM)
RevenueUS$420.32k
Cost of RevenueUS$472.49k
Gross Profit-US$52.17k
Other ExpensesUS$5.16m
Earnings-US$5.21m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.043
Gross Margin-12.41%
Net Profit Margin-1,240.37%
Debt/Equity Ratio1.6%

How did BELL perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BELL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BELL?

Other financial metrics that can be useful for relative valuation.

BELL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue280.9x
Enterprise Value/EBITDA-24.3x
PEG Ration/a

Price to Book Ratio vs Peers

How does BELL's PB Ratio compare to its peers?

BELL PB Ratio vs Peers
The above table shows the PB ratio for BELL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average3.9x

Price-To-Book vs Peers: BELL is expensive based on its Price-To-Book Ratio (5.3x) compared to the peer average (3.9x).


Price to Earnings Ratio vs Industry

How does BELL's PE Ratio compare vs other companies in the U.K. Medical Equipment Industry?

Price-To-Book vs Industry: BELL is expensive based on its Price-To-Book Ratio (5.3x) compared to the UK Medical Equipment industry average (2.2x)


Price to Book Ratio vs Fair Ratio

What is BELL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BELL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BELL's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BELL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BELL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BELL's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BELL's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Belluscura forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


81.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BELL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.9%).

Earnings vs Market: BELL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BELL is expected to become profitable in the next 3 years.

Revenue vs Market: BELL's revenue (70.3% per year) is forecast to grow faster than the UK market (4.1% per year).

High Growth Revenue: BELL's revenue (70.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BELL's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Belluscura performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-22.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BELL is currently unprofitable.

Growing Profit Margin: BELL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BELL is unprofitable, and losses have increased over the past 5 years at a rate of 22.3% per year.

Accelerating Growth: Unable to compare BELL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BELL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.3%).


Return on Equity

High ROE: BELL has a negative Return on Equity (-21.13%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Belluscura's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BELL's short term assets ($19.0M) exceed its short term liabilities ($931.7K).

Long Term Liabilities: BELL's short term assets ($19.0M) exceed its long term liabilities ($400.7K).


Debt to Equity History and Analysis

Debt Level: BELL has more cash than its total debt.

Reducing Debt: Insufficient data to determine if BELL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BELL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BELL has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 27.3% each year.


Discover healthy companies

Dividend

What is Belluscura current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BELL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BELL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BELL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BELL's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BELL has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average board tenure


CEO

Bob Rauker

no data

Tenure

US$375,339

Compensation

Mr. Robert Rauker, also known as Bob, is Chief Executive Officer of Belluscura plc and has been its Director since August 18, 2016. He serves as Chief Executive Officer and Director of Belluscura Ltd. Mr....


CEO Compensation Analysis

Compensation vs Market: Bob's total compensation ($USD375.34K) is about average for companies of similar size in the UK market ($USD335.04K).

Compensation vs Earnings: Bob's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: BELL's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7%.


Top Shareholders

Company Information

Belluscura plc's employee growth, exchange listings and data sources


Key Information

  • Name: Belluscura plc
  • Ticker: BELL
  • Exchange: AIM
  • Founded: 2015
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: UK£107.286m
  • Shares outstanding: 121.23m
  • Website: https://www.belluscura.com

Number of Employees


Location

  • Belluscura plc
  • 15 Fetter Lane
  • Holbom
  • London
  • Greater London
  • EC4A 1BW
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/25 00:00
End of Day Share Price2022/06/24 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.